Articles by C. Daniel Mullins, PhD

Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.

The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer
ByNour A. Obeidat, PhD,Francoise G. Pradel, PhD,Ilene H. Zuckerman, PhD,James A. Trovato, PharmD, MBA, BCOP,Francis B. Palumbo, PhD, JD,Sylvain DeLisle, MD, MBA,C. Daniel Mullins, PhD Among Medicare enrollees with metastatic colorectal cancer, the use of newer chemotherapy agents was lower for African American patients and for older patients.

Healthcare Utilization and Cost Effects of Prior Authorization for Pregabalin in Commercial Health Plans
ByJay M. Margolis, PharmD,Zhun Cao, PhD,Eberechukwu Onukwugha, PhD,Robert J. Sanchez, MS,Jose Alvir, DrPH,Ashish V. Joshi, PhD,C. Daniel Mullins, PhD Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.

Effects of a Medicaid Prior Authorization Policy for Pregabalin
ByJay M. Margolis, PharmD,Stephen S. Johnston, MA,Bong-Chul Chu, PhD,Eberechukwu Onukwugha, PhD,Kyle Hvidsten, MPH,Jose Alvir, DrPH,Joseph G. Rossi, PharmD,C. Daniel Mullins, PhD State Medicaid programs’ pregabalin prior authorization accomplished the objective of lower pregabalin utilization; the unintended effects were increased opioid use and increased disease-related healthcare costs.


The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific Approach
ByEbere Onukwugha, PhD,Ilene H. Zuckerman, PharmD, PhD,Diane McNally, BSPharm, MS,Karin S. Coyne, PhD, MPH,Vasudha Vats, MPH,C. Daniel Mullins, PhD 

Drug Therapy Persistence and Stroke Recurrence
ByFadia T. Shaya, PhD, MPH,Antoine C. El Khoury, PhD,C. Daniel Mullins, PhD,Dongyi Du, MSc,Richard Skolasky, MA,Hugh Fatodu, RPh,Howard Garber, MD, MPH,Matthew R. Weir, MD 

Impact of an Educational Intervention for Secondary Prevention of Myocardial Infarction on Medicaid Drug Use and Cost
ByIlene H. Zuckerman, PharmD,Sheila R. Weiss, PhD,Diane McNally, BPharm, MS,Barbara Layne, RN,C. Daniel Mullins, PhD,Junling Wang, MS 
